Division of Cardiovascular Medicine, Department of Medicine, School of Medicine, Jichi Medical University, Tochigi, Japan.
CureApp Institute, Karuizawa, Japan.
J Clin Hypertens (Greenwich). 2021 May;23(5):923-934. doi: 10.1111/jch.14191. Epub 2021 Jan 23.
Hypertension is the most considerable but treatable risk factor for cardiovascular disease. Although physicians prescribe multiple antihypertensive drugs and promote lifestyle modifications, the real-world blood pressure (BP) control rate remains poor. To improve BP target achievement, we developed a novel digital therapeutic-the HERB software system -to manage hypertension. Here, we performed a randomized pilot study to assess the safety and efficacy of the HERB system for hypertension. We recruited 146 patients with essential hypertension from March 2018 to March 2019. We allocated eligible patients to the intervention group (HERB system + standard lifestyle modification) or control group (standard lifestyle modification alone). The primary outcome was the mean change from baseline to 24 weeks in 24-hour systolic BP (SBP) measured by ambulatory blood pressure monitoring (ABPM). The baseline characteristics in each group were well balanced; the mean age was approx. 57 years, and 67% were male. In the primary end point at 24 weeks, HERB intervention did not lower the mean change of 24-hour SBP by ABPM compared with the controls (adjusted difference: -0.66 mmHg; p = .78). In an exploratory analysis focusing on antihypertensive drug-naïve patients aged <65, the effects of the HERB intervention were significantly greater than the control for reducing 24-hour SBP by ABPM at 16 weeks (adjusted difference: -7.6 mmHg; p = .013; and morning home SBP at 24 weeks (adjusted difference - 6.0 mmHg; p = .012). Thus, the HERB intervention did not achieve a primary efficacy end point. However, we observed that antihypertensive drug-naïve adult hypertensive patients aged <65 years could be a potential HERB system-effective target for further investigations of the efficacy of the system.
高血压是心血管疾病最重要但可治疗的危险因素。尽管医生开出了多种降压药并提倡生活方式的改变,但现实世界中的血压(BP)控制率仍然很差。为了提高 BP 达标率,我们开发了一种新的数字治疗方法——HERB 软件系统,用于管理高血压。在这里,我们进行了一项随机试点研究,以评估 HERB 系统治疗高血压的安全性和有效性。我们招募了 2018 年 3 月至 2019 年 3 月期间的 146 名原发性高血压患者。我们将符合条件的患者分为干预组(HERB 系统+标准生活方式改变)或对照组(仅标准生活方式改变)。主要结局是通过动态血压监测(ABPM)测量的 24 小时收缩压(SBP)从基线到 24 周的平均变化。两组的基线特征平衡良好;平均年龄约为 57 岁,67%为男性。在 24 周的主要终点时,与对照组相比,HERB 干预并没有降低 ABPM 测量的 24 小时 SBP 的平均变化(调整后的差异:-0.66mmHg;p=0.78)。在一项侧重于年龄<65 岁且未服用降压药的患者的探索性分析中,与对照组相比,HERB 干预在降低 ABPM 测量的 24 小时 SBP 方面的效果在 16 周时显著更大(调整后的差异:-7.6mmHg;p=0.013;在 24 周时,早晨家庭 SBP 也更低(调整后的差异为-6.0mmHg;p=0.012)。因此,HERB 干预未达到主要疗效终点。然而,我们观察到,年龄<65 岁且未服用降压药的成年高血压患者可能是 HERB 系统疗效的一个潜在目标人群,值得进一步研究该系统的疗效。